The first prospective randomized trial to demonstrate improved clinical outcome with any systemic therapy found selumetinib achieved tumor shrinkage in patients with metastatic uveal melanoma, according to data presented at ASCO 2013.
NEPA offers patients with cancer improved relief from nausea and vomiting from chemotherapy compared to palonosetron alone, according to data presented at ASCO 2013.
Individualizing treatment intensification based on early serum tumor marker declines improves PFS among men with poor-prognosis germ cell tumors, found research presented at ASCO 2013.
When combined with selective IACT, proton beam therapy appears to be as safe and effective as surgery in treating locally advanced tongue cancer, found research presented at ASCO 2013.
PF-05280014, a potential biosimilar, was found to have an identical amino acid sequence and similar in vitro functional properties as the monoclonal antibody (mAb) trastuzumab, found research presented at ASCO 2013.
Combining trastuzumab and chemotherapy may behave as a vaccine, allowing patients to respond immunologically, according to research presented at ASCO 2013.
For patients with asymptomatic/mildly symptomatic mCRPC without prior chemotherapy, abiraterone acetate plus prednisone is safe and extends PFS, according to research presented at ASCO 2013.
Please login or register first to view this content.
